Kathmandu, October 8
The people who have been given the Vero Cell Covid-19 vaccine are found to have developed 72.4 per cent antibodies in Nepal, more than those who have been administered Covishield, according to a recent study.
The people who have been vaccinated with Covishield are found to have developed 63.3 per cent antibodies, according to research conducted by the Nepal Health Research Council.
A total of 1,796 respondents from the Kathmandu valley (Kathmandu, Lalitpur and Bhaktapur districts) participated in the research.
There might be different results from the two types of vaccines as the research had taken place long after Covishield were administered to people as compared to Vero Cell, says senior research officer Dr Megha Nath Dhimal at a press conference organised here today by the council.
The study based in three districts of the Kathmandu valley showed that 65 per cent of vaccinated people had developed antibodies against the virus while 43.9 per cent of the unvaccinated people had also the presence antibody, according to senior research officer Dhimal.
Likewise, it was 55.1 per cent among those receiving the first dose of the vaccines followed by 82 per cent among the fully vaccinated.